[Skip to Content]
[Skip to Content Landing]
Comment & Response
December 17, 2014

Assessment of Outcomes of Hepatitis C Treatment

Author Affiliations
  • 1Medica Sur Clinic and Foundation, Mexico City, Mexico
  • 2Instituno Nacional de Salud Publica, Mexico City, Mexico

Copyright 2014 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.

JAMA. 2014;312(23):2570-2571. doi:10.1001/jama.2014.14900

To the Editor The review by Dr Kohli and colleagues1 illustrated how hepatitis C virus (HCV) treatment has moved from the low efficacy and high complication rates observed with ribavirin plus interferon to the high sustained viral response (SVR) and rare complication rates observed with directly acting antivirals. Directly acting antivirals have been embraced by clinical guidelines2 and, given their comparable safety and efficacy, the discussion over which specific drug will be used in the near future has turned to availability and affordability. Yet in the midst of this discussion is a more clinically relevant question: now that SVR and safety seem assured, should the outcomes of HCV treatment be redefined?

First Page Preview View Large
First page PDF preview
First page PDF preview